|
|
12701, Commonwealth Drive, Suite 5
Fort Myers, FL 33913 USA
phone:(239) 768-0600
fax:(239) 768-0711
|
|
| Symbol |
NGNM |
| Exchange |
OTC |
| Founded |
2001 |
| Employees |
205 |
|
|
| www.neogenomics.com
|
|
| Research Sector |
Healthcare Services |
|
 |
| Summary Description |
| Cancer genetics testing laboratory |
|
| Management |
| Douglas VanOort, Chairman & Chief Executive Officer; Steven Jones, Executive Vice President - Finance & Director of Investor Relations; Robert P. Gasparini, M.S., Chief Science Officer; Rob Horel, Vice President, Sales & Marketing; George Cardoza, Chief Financial Officer; Maher Albitar, M.D., Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, pathology, cancer genetics testing, molecular diagnostics |
|
|
|
| Description |
|
NeoGenomics Laboratories is a high-complexity cancer genetics laboratory that addresses the anatomic pathology and oncology markets’ inquiries related to diagnosis, prognosis, and therapy selection for hematologic and solid tumor cancers. The Company offers cytogenetic studies, which often answer questions in the treatment of hematologic malignancies; immunohistochemistry, which is used in the diagnosis of abnormal cells; fluorescence in-situ Hybridization, which detects and locates the presence or absence of specific DNA sequences on chromosomes; flow cytometry, which rapidly measures the characteristics of individual cells and thereby determines malignancy; and molecular genetics, a rapidly emerging cancer diagnostic branch. |
|
| Products / Services |
The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. All of these testing services are widely utilized in the diagnosis and prognosis of various types of cancer.
|
|
| Technology / Differentiation |
| NeoGenomics has a strategic partnership with Abbott Molecular to develop and launch three laboratory developed tests based on Abbott's extensive intellectual property portfolio in molecular genetics. The first such test, a FISH-based test to aid in the diagnosis of Melanoma was launched in 2010. The next two tests will be launched over the next 2-3 years. |
|
| Market / Customers |
The Company address the cancer testing market with a variety of genetic and molecular testing modalities.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
